Ulcerative colitis (UC) is a type of inflammatory bowel disease (IBD) characterized by chronic gastrointestinal inflammation. In most patients, the disease cycles through periods of remission and exacerbations. The complex etiology involves multiple factors including environmental, genetic, and immune causal elements. Janus Kinase (JAK) family is an essential component of a cytokine-signaling cascade partially responsible for the pathogenesis of UC. Treating UC presents difficulties despite various therapeutic options. Medications that block the JAK-signaling pathway can interfere with the inflammatory pathway of UC and possibly reduce symptoms and frequency of exacerbations. Tofacitinib is an oral pan-JAK inhibitor, primarily of JAK1 and JAK3, that was recently approved by the Food and Drug Administration (FDA) for the chronic treatment of UC in 2018. The following review describes the newly approved Janus kinase inhibitor, tofacitinib, including its pharmacokinetic properties, efficacy and safety data, and potential place in therapy.
RubinDTAnanthakrishnanANSiegelCASauerBGLongMD. ACG clinical guideline: ulcerative colitis in adults. Am J Gastroenterol. 2019;114(3):384–413.
2.
AbrahamCDulaiPSVermeireSSandbornWJ. Lessons learned from trials targeting cytokine pathways in patients with inflammatory bowel diseases. Gastroenterol. 2017;152(2):e374–388.
3.
FumeryMSinghSDulaiPSGower-RousseauCPeyrin-BirouletLSandbornWJ. Natural history of adult ulcerative colitis in population-based cohorts: a systematic review. Clin Gastroenterol Hepatol. 2018;16(3):343–356.
4.
KoCWSinghSFeuersteinJD, et al.American gastroenterological association institute guideline on the management of mild-to-moderate ulcerative colitis. Gastroenterol. 2019;156(3):748–764.
5.
Tofacitinib [package insert]. Pfizer Labs; 2018.
6.
YamaokaKSaharinenPPesuMHoltVESilvennoinenOO’SheaJJ. The Janus kinases (Jaks). Genome Biol. 2004;5(12):253.
7.
BolandBSSandbornWJChangJT. Update on Janus kinase antagonists in inflammatory bowel disease. Gastroenterol Clin North Am. 2014;43(3):603–617.
8.
DowtyMELinJRyderTF, et al.The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a Janus kinase inhibitor, in humans. Drug Metab Dispos. 2014;42(4):759–773.
9.
KrishnaswamiSBoyMChowVChanG. Safety, tolerability, and pharmacokinetics of single oral doses of tofacitinib, a Janus kinase inhibitor, in healthy volunteers. Clin Pharm Drug Dev. 2014;4(2):83–88.
10.
LambaMWangRFletcherTAlveyCKushnerIV JStockTC. Extended-release once-daily formulation of tofacitinib: evaluation of pharmacokinetics compared with immediate-release tofacitinib and impact of food. J Clin Pharmacol. 2016;56(11):1362–1371.
11.
VeeravalliVDashRPThomasJABabuRJMadgulaLMSrinivasNR. Critical assessment of pharmacokinetic drug-drug interaction potential of tofacitinib, baricitinib and upadacitinib, the three approved Janus kinase inhibitors for rheumatoid arthritis treatment. Drug Saf. 2020;43(8):711–725. doi:10.1007/s40264-020-00938-z
12.
GuptaPChowVWangR, et al.Evaluation of the effect of fluconazole and ketoconazole on the pharmacokinetics of tofacitinib in healthy adult subjects. Clin Pharmacol Drug Dev. 2014;3(1):72–77.
13.
SandbornWJGhoshSPanesJ, et al.Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med. 2012;367(7):616–624.
14.
LewisJDChuaiSNesselLLichtensteinGRAberraFNEllenbergJH. Use of the non-invasive components of the mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis. 2008;14(12):1660–1666.
15.
SandbornWJChinyuSSandsBE, et al.Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376(18):1723–1736.
16.
WeisshofRGolanMASossenheimerPH, et al.Real-world experience with tofacitinib in IBD at a tertiary center. Dig Dis Sci. 2019;64(7):1945–1951. doi:10.1007/s10620-019-05492-y
17.
MukherjeeAHazraASmithMK, et al.Exposure-response characterization of tofacitinib efficacy in moderate to severe ulcerative colitis: results from a dose-ranging phase 2 trial. Br J Clin Pharmacol. 2018;84(6):1136–1145.
18.
MotoyaSWatanabeMKimHJ, et al.Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studies. Intest Res. 2018;16(2):233–245.
19.
HanauerSPanaccioneRDaneseS, et al.Tofacitinib induction therapy reduces symptoms within 3 days for patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2019;17(1):139–147.
20.
PanesJVermeireSLindsayJO, et al.Tofacitinib in patients with ulcerative colitis: health-related quality of life in phase 3 randomised controlled induction and maintenance studies. J Crohns Colitis. 2018;12(2):145–156.
21.
WinthropKLYamanakaHValdezH, et al.Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheumatol. 2014;66(10):2675–2684.
22.
WinthropKLLebwohlMCohenAD, et al.Herpes zoster in psoriasis patients treated with tofacitinib. J Am Acad Dermatol. 2017;77(2):302–309.
23.
WinthropKLMelmedGYVermeireS, et al.Herpes zoster infection in patients with ulcerative colitis receiving tofacitinib. Inflamm Bowel Dis. 2018;24(10):2258–2265.
24.
Long-term study of CP-690,550 in subjects with ulcerative colitis (OCTAVE). U.S. National Library of Medicine. Published 2011. Updated November 13, 2019. Accessed November 22, 2019. Clinicaltrials.gov/ct2/show/NCT01470612
25.
MahadevanUDubinskyMCSuC, et al.Outcomes of pregnancies with maternal/paternal exposure in the tofacitinib safety databases for ulcerative colitis. Inflamm Bowel Dis. 2018;24(12):2494–2500.
26.
SandbornWJPanesJD’HaensGR, et al.Safety of tofacitinib for treatment of ulcerative colitis, based on 4.4 years of data from Global Clinical Trials. Clin Gastroenterol Hepatol. 2019;17(8):1541–1550. doi:10.1016/j.cgh.2018.11.035
27.
FeaganBGLaschKLissoosT, et al.Rapid response to vedolizumab therapy in biologic-naïve patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2019;17(1):130–138.
28.
BouriSHartAL. How quickly do inflammatory bowel disease medications really work?Clin Gastroenterol Hepatol. 2019;17(1):34–35.
29.
ChateauTBerreCLPeyrin-BirouletL. Will the placebo effect disappear with new targets for treatment of inflammatory bowel diseases?Clin Gasterol Hepatol. 2020;18(5):1030–1032.
30.
JairathVZouGYParkerCE. Placebo response and remission rates in randomized trials of induction and maintenance therapy for ulcerative colitis. Cochrane Database Syst Rev. 2017(9):CD011572.
